REPORT – ERYTECH ’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 2 4 , 20 22 Cambridge, MA (U.S.) and Lyon (France), June 24 , 2022 – ERYTECH Pharma ( Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
Monthly information related to total number of voting rights and shares composing the share capital _May 3 1 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 2 4 , 20 22 Cambridge, MA (U.S.) and Lyon (France), May 24 , 2022 – ERYTECH Pharma ( Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
ERYTECH to P resent at the H.C. Wainwright Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 1 7 , 2022 – ERYTECH Pharma ( Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
Monthly information related to total number of voting rights and shares composing the share capital – April 30 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
ERYTECH Provides Business and Financial Update for the First Quarter of 20 2 2 Conference call and webcast on Friday, May 13, 2022 at 8:30am EDT / 02:30pm CEST U.S. cell therapy manufacturing facility sold to Catalent for a total consideration of USD 44.5 million Progress towards seeking
ERYTECH Announces Filing of 202 1 Universal Registration Document and 202 1 Annual Report on Form 20-F , as well as its 2022 financial calendar Cambridge, MA (U.S.) and Lyon (France), April 28 , 202 2 – ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical
ERYTECH Sell s U. S. Manufacturing Facility and Enter s Long-Term Supply Agreement with Catalent Catalent a cquire d ERYTECH’s U.S. c ell t herapy m anufacturing f acility for a t otal c onsideration of USD 44.5 m illion ERYTECH and Catalent to e nter into a l ong- t erm s upply a greement
ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology The study confirms the potential of eryaspase (GRASPA®) as an attractive treatment option f or acute lymphoblastic leukemia (ALL ) patients with
Monthly information related to total number of voting rights and shares composing the share capital – March 31 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
